Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A clinical study of SIM-0508 in patients with locally advanced/metastatic solid tumor in both China and the United States

Next Previous
X
Search
Trial Profile

A clinical study of SIM-0508 in patients with locally advanced/metastatic solid tumor in both China and the United States

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 19 Sep 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs SIM 0508 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions

    • Most Recent Events

    • 19 Sep 2024 New trial record
    • 29 Aug 2024 According to a Simcere media release, company announced that the investigational new drug (IND) application of SIM0508 has been approved by the Food and Drug Administration (FDA). The has been cleared to carry out clinical trials in patients with locally advanced/metastatic solid tumor in both China and the United States.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top